ARGX 250516 590.00P(ARGX250516P590000) Stock Price Today

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

ARGX250516P590000

Watchlist

34.16
+2.96+9.49%

15min DelayClose May 9 16:00 ET

35.52High21.05Low

Intraday

5D
Daily

News

A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $700 to $1,065
Moomoo NewsMay 10 09:00 ET · Ratings
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
BenzingaMay 9 19:45 ET
Express News | Oppenheimer Maintains Outperform on Argenx, Raises Price Target to $708
BenzingaMay 9 13:48 ET
Express News | Guggenheim Maintains Buy on Argenx, Lowers Price Target to $1065
BenzingaMay 9 12:35 ET
Argenx SE (ARGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain
Yahoo FinanceMay 9 10:25 ET
Citigroup Maintains Buy on Argenx, Raises Price Target to $803
BenzingaMay 9 10:14 ET · Ratings

Comments

Teddy123

Apr 11 15:30

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

$argenx SE (ARGX.US)$
Game-Changing FDA Approval: VYVGART's New 30-Second Self-Injection Transforms Patient Care

Teddy123

Apr 8 13:30

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

$argenx SE (ARGX.US)$
Clinical Data Breakthrough: VYVGART Achieves 75% Success in gMG Patients, Transforms CIDP Treatment

Teddy123

Mar 7 18:53

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

$argenx SE (ARGX.US)$
Can This New Long-term Data Cement VYVGART as the Leading gMG Treatment?

Money Thrill

Nov 12, 2024 17:38

European Morning news [MarketDevil]

$argenx SE (ARGX.US)$ (ABM FN) China's regulator has approved the Supplemental Biologics License Application for Vyvgart Hytrulo for the treatment of adults suffering from CIDP. The biotech company announced this after the close.
This approval followed the Adhere study.This concerns an injection of 1,000 milligrams that can be administered once a week. About 50,000 people in China suffer from CIDP.
“It is the first and only treatment approved in China for CIDP,”...

Money Thrill

Nov 3, 2024 03:19

European News from journal HLN (LeatestNewsJournal)

$argenx SE (ARGX.US)$ Last quarter, the company recorded a net profit of 91.4 million euros, compared to a net loss of 72.6 million euros in the same period last year. After nine months there is a net profit of 58.9 million euros against a net loss of 195.9 million euros.
The difference between the operational results and the net result is mainly made up of the financial results and the taxes on the result. At the end of September, Argenx still h...